LLY

1,018.6

+3.3%↑

JNJ

229.93

+0.53%↑

ABBV

213.62

+1.94%↑

UNH

389.29

-0.09%↓

AZN

184.71

+0.4%↑

LLY

1,018.6

+3.3%↑

JNJ

229.93

+0.53%↑

ABBV

213.62

+1.94%↑

UNH

389.29

-0.09%↓

AZN

184.71

+0.4%↑

LLY

1,018.6

+3.3%↑

JNJ

229.93

+0.53%↑

ABBV

213.62

+1.94%↑

UNH

389.29

-0.09%↓

AZN

184.71

+0.4%↑

LLY

1,018.6

+3.3%↑

JNJ

229.93

+0.53%↑

ABBV

213.62

+1.94%↑

UNH

389.29

-0.09%↓

AZN

184.71

+0.4%↑

LLY

1,018.6

+3.3%↑

JNJ

229.93

+0.53%↑

ABBV

213.62

+1.94%↑

UNH

389.29

-0.09%↓

AZN

184.71

+0.4%↑

Home・Akcijų sąrašas・Pacific Biosciences of California Inc

Pacific Biosciences of California Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

1.14

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

1.12

Max

1.18

Pagrindiniai rodikliai
By Trading Economics
Pajamos	32M -8.3M
Pardavimai	-7.5M 37M
Pelnas, tenkantis vienai akcijai	-0.12
Pelno marža	-22.258
Darbuotojai	485
EBITDA	509K -38M

Rekomendacijos
By TipRanks
Rekomendacijos	Neutralu
12 mėnesių prognozė	+112.5% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-08-06

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	-60M 421M
Ankstesnė atidarymo kaina	1.14
Ankstesnė uždarymo kaina	1.14

Naujienos nuotaikos

By Acuity

64%

36%

293 / 345 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Bullish Evidence

1.13 / N/A Palaikymas ir pasipriešinimas

Pacific Biosciences of California Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-05-18 23:10; UTC

Karštos akcijos

Stocks to Watch: Agilysys, XP

2026-05-18 18:44; UTC

Pagrindinės rinkos jėgos

Claritev Shares Recover After Comments About DOJ

2026-05-18 23:55; UTC

Uždarbis

Review & Preview: Earnings' Last Gasp -- Barrons.com

2026-05-18 23:47; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-05-18 23:47; UTC

Rinkos pokalbiai

Nikkei May Rise on Hopes for U.S.-Iran Deal -- Market Talk

2026-05-18 23:37; UTC

Rinkos pokalbiai

Gold Rises Amid Hopes for U.S.-Iran Peace Deal -- Market Talk

2026-05-18 22:31; UTC

Įsigijimai, susijungimai, perėmimai

Lens Technology Ju Teng International Shares to Resume Trading on Hong Kong Exchange on May 19

2026-05-18 22:30; UTC

Įsigijimai, susijungimai, perėmimai

Lens Technology: Acquisition of Remaining Ju Teng International Shares to Cost HK$1.91B

2026-05-18 22:30; UTC

Įsigijimai, susijungimai, perėmimai

Lens Technology to Make Offer for Remainder Shares of Ju Teng International Only After Completion of Stake Purchase

2026-05-18 22:25; UTC

Įsigijimai, susijungimai, perėmimai

Lens Technology to Acquire 333.71M Ju Teng International Shares for HK$2.20 Each

2026-05-18 22:24; UTC

Įsigijimai, susijungimai, perėmimai

Lens Technology to Acquire 27.81% Stake in Ju Teng International for HK$734.17M

2026-05-18 20:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2026-05-18 20:50; UTC

Rinkos pokalbiai

Įsigijimai, susijungimai, perėmimai

Financial Services Roundup: Market Talk

2026-05-18 20:25; UTC

Uždarbis

Correct: XP 1Q Total Client Assets BRL1.53T

2026-05-18 20:23; UTC

Uždarbis

XP 1Q Total Client Assets BRL1.53B

2026-05-18 20:19; UTC

Uždarbis

XP 1Q Adj EPS BRL2.49 >XP

2026-05-18 20:19; UTC

Uždarbis

XP 1Q Rev BRL4.73B >XP

2026-05-18 19:10; UTC

Rinkos pokalbiai

Oil Presses Higher With No Hormuz Reopening in Sight -- Market Talk

2026-05-18 19:00; UTC

Uždarbis

5 Stocks with 5% Yields and Market-Beating Returns -- Barrons.com

2026-05-18 18:52; UTC

Rinkos pokalbiai

U.S. Natural Gas Futures Gain As Weather Heats Up -- Market Talk

2026-05-18 18:17; UTC

Rinkos pokalbiai

Įsigijimai, susijungimai, perėmimai

NextEra's Dominion Acquisition Unlikely to Spur Wider Utility Consolidation -- Market Talk

2026-05-18 17:22; UTC

Rinkos pokalbiai

Tokenized Assets Expected to be Over $1T By 2030 -- Market Talk

2026-05-18 16:57; UTC

Įsigijimai, susijungimai, perėmimai

The Long Regulatory Road Ahead for the NextEra-Dominion Deal -- Barrons.com

2026-05-18 16:57; UTC

Rinkos pokalbiai

Global Energy Roundup: Market Talk

2026-05-18 16:57; UTC

Rinkos pokalbiai

Commodities Higher as Traders Want Physical Assets -- Market Talk

2026-05-18 16:54; UTC

Įsigijimai, susijungimai, perėmimai

Vinci Doesn't Set Out Financial Details of Deal

2026-05-18 16:50; UTC

Įsigijimai, susijungimai, perėmimai

Vinci: Acquisition of New Brunswick-Based Group Stregthens Presence in Eastern Canada

2026-05-18 16:49; UTC

Įsigijimai, susijungimai, perėmimai

Vinci: Modern Group is Roadwork, Civil Engineering Specialist

2026-05-18 16:49; UTC

Įsigijimai, susijungimai, perėmimai

Vinci: Modern Group Made Revenue of Around 50 Mln Euros Last Year

2026-05-18 16:48; UTC

Įsigijimai, susijungimai, perėmimai

Vinci Buys Canada's Modern Group of Companies

Akcijų palyginimas

Kainos pokytis

Pacific Biosciences of California Inc Prognozė

Kainos tikslas

By TipRanks

112.5% į viršų

12 mėnesių prognozė

Vidutinis 2.38 USD 112.5%

Aukščiausias 3 USD

Žemiausias 1.5 USD

Remiantis 4 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Pacific Biosciences of California Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Neutralu

4 ratings

Pirkti

Laikyti

Parduoti

Remiantis 4 analitikų, pateikusių Pacific Biosciences of California Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

1.13 / N/APalaikymas ir pasipriešinimas

Recent bullish events outweigh bearish events.

Bearish events outweigh bullish events.

There is one bearish event.

Rinkos nuotaikos

By Acuity

293 / 345 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Pacific Biosciences of California Inc

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solution to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-red sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. In addition, it provides revio system + sequel systems which conduct, monitor, and analyze single-molecule biochemical reactions in real time; SBB short-read sequencing; onso instrument conducts, monitors, and analyzes SBB biochemical reactions; and SBB consumable, including flow cells, clustering, and sequencing reagent kits. The company serves academic and governmental research institutions; commercial testing and service laboratories; genome centers; public health labs, hospitals and clinical research institutes, and contract research organizations; pharmaceutical companies; and agricultural companies. It markets its products through a sales force and distribution partners in Asia, Australia, Europe, the Middle East, Africa, and Latin America. It has a development and commercialization agreement with Invitae Corporation; and a collaboration with Radboud University Medical to explore genetic causes of rare and genetic diseases. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.